Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib Full Text
Clinical Cancer Research, 11/14/2010
Heon S et al. – The data suggest a lower risk of CNS progression in patients with advanced NSCLC and somatic EGFR mutations initially treated with gefitinib or erlotinib compared with published rates of 40% in historical series of advanced NSCLC patients.
Methods- Patients with stage IIIB/IV NSCLC with somatic EGFR mutations initially treated with gefitinib or erlotinib were identified
- Cumulative risk of CNS progression calculated using death as competing risk
- Of 100 patients, 19 had BM at the time of diagnosis of advanced NSCLC; seventeen of them received CNS therapy before initiating gefitinib or erlotinib
- 84 patients have progressed after median potential follow-up of 42.2 months
- Median time to progression 13.1 months
- 28 patients developed CNS progression, 8 of whom had previously treated BM
- 1- and 2-year actuarial risk of CNS progression 7% and 19%
- Patient age and EGFR mutation genotype significant predictors of the development of CNS progression
- Median OS for entire cohort 33.1 months
